Compare IDEXX Laboratories, Inc. (IDXX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Progressive Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Progressive Corp trades at $217.43 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 3.1× IDEXX Laboratories, Inc.'s market cap, and Progressive Corp pays a 0.18% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Progressive Corp for 81 Days on average.
| IDXX | PGR | |
|---|---|---|
Market Cap | $40.43B | $126.95B |
Volume | 692,164 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $766.68 | $242.16 |
52-Week Low | $504.70 | $190.40 |
Typical Hold Time | 46 Days | 81 Days |
Enterprise Value | $41.32B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
PGR trades at $218.73, up 2.15% on the day, with a bullish technical signal and strong fundamentals. Revenue has grown from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. The stock is supported by a consensus price target of $222.23 and positive analyst sentiment, though RSI levels suggest some near-term overbought conditions.
The outlook for PGR is positive, driven by consistent earnings beats and robust profitability metrics like a 34.94% ROE. Risks include competitive pressures in personal auto insurance and potential market volatility. The stock offers a solid investment opportunity with upside to the price target, but investors should monitor underwriting discipline amid industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
